Delivery Order SPE2DR25D9331-SPE2DR26FQQB4
- Not listed
- The Defense Logistics Agency awarded a $79,430.86 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Perjeta 420 mg/14 mL vials. The award, issued on November 13, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation and was issued without subcontractor involvement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite...
- The Defense Logistics Agency issued a delivery order valued at $4,905.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on January 2, 2026, with an ultimate completion date of January 26, 2026, operates under a firm fixed-price contract structure with no set-aside designation. This award falls under DMS Pharmaceutical Group's Pharmaceutical Prime...
- The Defense Logistics Agency awarded a $49,058.10 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on January 13, 2026, with an ultimate completion date of February 4, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award is issued under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a $46,509.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 2, 2025, with an ultimate completion date of December 23, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. DMS Pharmaceutical Group was selected as...
- The Defense Logistics Agency awarded a $41,858.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The Defense Logistics Agency issued a delivery order valued at $46,509.80 to DMS Pharmaceutical Group Inc. for Perjeta 420 mg/14 ml vials, a oncology therapeutic product. The order was awarded on December 11, 2025, with an ultimate completion date of January 5, 2026, under a firm fixed-price contract structure with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform work at its Park...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $46,509.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The award was issued on November 13, 2025, with an ultimate completion date of December 5, 2025, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge facility with an ultimate completion date of October 10, 2025. The award was issued on September 19, 2025, without a set-aside designation, allowing...
- The Defense Logistics Agency awarded a $27,343.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, represents a focused procurement action without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- SPE2DR25D9331Indefinite Delivery Contract
- SPE2DR25D9331-SPE2DR26FQQB4Delivery Order
The Defense Logistics Agency awarded a $58,869.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order was issued on January 12, 2026, with an ultimate completion date of February 3, 2026, and carries no set-aside designation. This award represents a single delivery order issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (SPE2DR) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply solutions to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group, registered in the System for Award Management since July 2001, serves as a critical regional prime vendor contractor supplying branded and generic prescription medications, biologics, vaccines, and specialized pharmaceutical products to federal military medical facilities. The company's parent IDC, valued at up to $500 million with a completion date of December 31, 2036, enables the Defense Logistics Agency to issue firm fixed-price delivery orders for diverse pharmaceutical requirements across the military health system. Perjeta, a therapeutic oncology agent, aligns with the contractor's established portfolio of specialty pharmaceutical products supporting DoD healthcare operations, and this delivery order demonstrates continued performance under the broader PPV-G GEN V framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $58.9k | 1/11/26 |